Can celecoxib (Celebrex) be used for treatment of polymyalgia rheumatica?

No, celecoxib (Celebrex) should not be used as primary treatment for polymyalgia rheumatica

Glucocorticoids, not NSAIDs including celecoxib, are the strongly recommended first-line treatment for PMR. The 2015 EULAR/ACR guidelines explicitly state that clinicians should use glucocorticoids instead of NSAIDs in patients with PMR 1111111111. This represents a strong recommendation based on the fundamental pathophysiology of PMR as an inflammatory condition requiring immunosuppressive therapy.

Why Glucocorticoids Are Required

PMR is an inflammatory rheumatic condition affecting people over 50 years old, characterized by bilateral shoulder pain, hip/neck pain, and elevated inflammatory markers (ESR/CRP) 2. The disease responds dramatically to glucocorticoids, typically providing relief within 24-48 hours—a response so characteristic it helps confirm the diagnosis 1.

The recommended initial glucocorticoid dose is 12.5-25 mg prednisone equivalent daily 111. This should be tapered gradually:

• Reduce to 10 mg/day within 4-8 weeks
• Then taper by 1 mg every 4 weeks until discontinuation
• Total treatment duration ideally 12 months or less, though relapses are common (occurring in 34-76% of patients) 34

Limited Role for NSAIDs/Celecoxib

The guidelines make only one exception: NSAIDs and analgesics may be used short-term for pain related to OTHER conditions in PMR patients 1111. This means celecoxib could address concurrent osteoarthritis or mechanical pain, but it does not treat the underlying PMR inflammation.

Celecoxib is FDA-approved for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain 55—but notably NOT for PMR. The drug works by selectively inhibiting COX-2, reducing pain and inflammation in arthritis 67, but this mechanism is insufficient for the systemic inflammatory process of PMR.

When Glucocorticoids Alone Are Inadequate

If patients experience relapses, glucocorticoid-related adverse events, or require prolonged therapy, the guidelines conditionally recommend adding:

1. Methotrexate (7.5-10 mg/week orally) as a glucocorticoid-sparing agent 111
2. IL-6 receptor inhibitors (tocilizumab, sarilumab) - newer evidence shows these achieve higher remission rates and reduce glucocorticoid exposure 348

The 2024 treat-to-target recommendations emphasize that treatment targets include achieving and maintaining remission while preventing tissue ischemia and vascular damage—goals that require disease-modifying therapy, not symptomatic treatment with NSAIDs 3.

Critical Safety Considerations

Using celecoxib instead of glucocorticoids risks:

• Undertreating the inflammatory disease, allowing progression
• Missing concurrent giant cell arteritis (overlaps with PMR in 16-21% of cases), which requires urgent high-dose glucocorticoids to prevent blindness and stroke 3
• Delaying appropriate diagnosis if symptoms partially improve with NSAIDs but inflammatory markers remain elevated

Additionally, celecoxib carries cardiovascular risks that must be weighed carefully, particularly in the elderly PMR population who often have cardiovascular comorbidities 569.

Practical Algorithm

For suspected PMR:

1. Confirm diagnosis: Age >50, bilateral shoulder pain, elevated ESR/CRP, exclude other conditions
2. Screen for giant cell arteritis symptoms (headache, jaw claudication, vision changes)
3. Start prednisone 12.5-25 mg daily (lower dose if diabetes/osteoporosis present, higher if high relapse risk)
4. Expect dramatic improvement within days—if no response, reconsider diagnosis
5. Add methotrexate or IL-6 inhibitor if relapses occur or glucocorticoid toxicity develops
6. Reserve celecoxib only for concurrent non-PMR musculoskeletal pain

Celecoxib has no role as monotherapy or primary treatment for polymyalgia rheumatica.